All In MedTech

Device Trial Radar · NCT06750536

Evaluating the Safety and Performance of the MiniLung Petite Kit in Neonatal and Pediatric Patients With Acute Respiratory and Cardiac Failure

Last checked: Nov 20, 2026Latest source record: Dec 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Oct 12, 2025

Primary completion

Oct 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Xenios AGNot on our public-company list
Sponsor type
Industry
Collaborators
Alcedis GmbH
First posted
Dec 27, 2024

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, up to 8 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective observational study will evaluate the safety and performance of the MiniLung petite kit in neonatal and pediatric patients with acute respiratory and cardiac failure. The main question it aims to answer is (study hypotheses): Veno-venous (VV) and veno-arterial (VA) Extracorporeal Membrane Oxygenation (ECMO) using the MiniLung petite kit is safe and improves gas exchange (oxygenation and CO2 removal) and hemodynamic stabilization in neonatal and pediatric patients with severe acute respiratory and/or cardiopulmonary failure within 24 hours compared to the treatment before VV or VA ECMO initiation and maintain a life-sustaining condition.

Conditions

  • Extracorporeal Membrane Oxygenation Complication
  • Neonatal Aspiration Pneumonia
  • Acute Respiratory Failure
  • Acute Lung Injury

Interventions

  • MiniLung petite kit combined with the Xenios consoleDevice

    Veno-venous (VV) and veno-arterial (VA) Extracorporeal Membrane Oxygenation (ECMO) treatment will be performed using the MiniLung petite kit combined with the Xenios console according to their intended use and local standards/requirements.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Oxygenation IndexTime frame: Baseline and during the intervention every 24 hours until a maximum of 29 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Universitätsklinikum Mannheim

    Mannheim, Germany · Recruiting

  • Universitätsklinkum Bonn

    Bonn, North Rhine-Westphalia, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.